Autres langues Navamedic ASA

Actions

NAVA

NO0010205966

Produits pharmaceutiques

Marché Fermé - Oslo Bors 16:45:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
13,30 ^NOK	-1,48%		-0,37%	-44,12%

15/08	Transcript : Navamedic ASA, Q2 2026 Earnings Call, Aug 14, 2026
14/08	Navamedic ASA publie ses prévisions de résultats pour l'exercice 2026	CI

Autres langues

02/09	Navamedic ASA: Mandatory notification of trade
14/08	Navamedic Asa Provides Earnings Guidance for the Year 2026
14/08	Navamedic ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
14/08	Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026
10/08	Navamedic ASA: Invitation to presentation of second quarter and first half year 2026 results
26/06	Navamedic ASA: Mandatory notification of trade
16/06	Navamedic ASA Announces CEO Changes
16/06	Navamedic CEO Steps Down; Successor Named
16/06	Navamedic ASA: Change in leadership
04/06	Major shareholdings notification
21/05	Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet
21/05	Navamedic Asa Launches Virono The First Single Dose Over The Counter Cold Sore Tablet
20/05	Major shareholder disclosure in Navamedic ASA
18/05	Navamedic ASA: Mandatory notification of trade
23/04	Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2026
23/04	Navamedic ASA: Minutes of Annual General Meeting
23/04	Navamedic ASA: Steady performance and continued product launch in Q1 2026
20/04	Navamedic ASA: Invitation to presentation of first quarter 2026 results
15/04	Navamedic : Recommendation of the nomination committee 2026
15/04	Navamedic ASA: Recommendation of the nomination committee for the Annual General Meeting on 23 April 2026
31/03	Navamedic ASA: Notice of Annual General Meeting
17/03	Technology Group Cyviz Names Former Navamedic CFO to Same Role
27/02	Navamedic ASA: Mandatory notification of trade
12/02	Navamedic ASA: Strong growth and important product launch in Q4 2025
12/02	Navamedic ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025